Consensus Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Delayed NSE India S.E. 06:25:40 2024-03-28 am EDT 5-day change 1st Jan Change
1,007 INR +0.77% Intraday chart for Zydus Lifesciences Limited +1.43% +46.16%

Evolution of the average Target Price on Zydus Lifesciences Limited

Price target over the last 5 years

History of analyst recommendation changes

ef08b7bbdbbe2bc3a75b8b71d8bed9.fXZK6LbZUGJ8y1AwgxaTL_OK2tDI5EZFayD4HoIrfL8.MjkDg8a8Yhoppz8E5kHBQqen4pi4uzA_KmGVcLpONsUUHSWf9eF9EkuBYA~bbc293bb05d91cb5414080df4f7fb56c
Jefferies Adjusts Zydus Lifesciences’ Price Target to INR750 From INR660, Keeps at Hold MT
Indian shares set for a muted start, tracking Asian peers RE
India's Nifty set to open with slight gains, tracking Asia RE
Jefferies Adjusts Zydus Lifesciences’ Price Target to INR640 From INR630, Keeps at Hold MT
Indian Equities Close Higher on Friday as Major Central Banks Hold Rates Steady MT
Indian shares set for muted start as Fed rate worries, China concerns weigh RE
Nomura Adjusts Zydus Lifesciences' Price Target to INR747 From INR540, Keeps at Buy MT
Jefferies Downgrades Zydus Lifesciences to Hold From Buy, Adjusts Price Target to INR630 From INR585 MT
Indian shares set for muted open ahead of June quarter earnings RE
Indian shares set to open higher on Fed rate pause optimism RE
Jefferies Adjusts Zydus Lifesciences' Price Target to INR585 From INR575, Keeps at Buy MT
Indian shares to open lower on weak earnings, Fed rate hike worries RE
Indian shares set to fall on rate fears ahead of U.S. jobs data RE
Indian shares set to fall on rate fears after Powell's testimony RE
Indian shares set to open lower on Q3 growth slowdown, weak global cues RE
Nomura Adjusts Zydus Lifesciences' Price Target to INR540 From INR489, Keeps at Buy MT
Crisil Affirms AA+ Rating on Zydus Lifesciences' Bank Loans; Outlook Stable MT
Indian shares tipped to fall ahead Nov inflation data RE
Nomura Adjusts Cadila Healthcare's Price Target to 489 Indian Rupees From 481 Indian Rupees, Keeps at Buy MT
SENSEX 30 : Indian Indices Witness Strong Buying Midday; Cadila Healthcare Shares Soar 7% MT
Cadila Healthcare Limited Reports Audited Consolidated and Standalone Earnings Results for the Fourth Quarter and Year Ended March 31, 2016; Provides Tax Rate Guidance for the Year 2016 and 2017 CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
999.7 INR
Average target price
822 INR
Spread / Average Target
-17.78%
High Price Target
1,107 INR
Spread / Highest target
+10.73%
Low Price Target
550 INR
Spread / Lowest Target
-44.98%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Zydus Lifesciences Limited

Jefferies & Co.
Nomura
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings